Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24577563 | 0.83 | KIT (0.40) | KITKDM5BJAK2JAK1TYK2 | |
| SCHEMBL24577085 | 0.76 | KIT (0.39) | KITKDM5BJAK2JAK1TYK2 | |
| SCHEMBL24577874 | 0.75 | FLT3 (0.38) | KITJAK2JAK1TYK2 | |
| SCHEMBL24577209 | 0.72 | JAK2 (0.39) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL24577471 | 0.69 | BACE1 (0.40) | KDM5BJAK2 | |
| SCHEMBL24578878 | 0.69 | KDR (0.38) | — | |
| SCHEMBL15382055 | 0.67 | KIT (0.43) | KITKDM5BJAK2JAK1TYK2 | |
| SCHEMBL24578796 | 0.67 | MAP4K1 (0.31) | — | |
| SCHEMBL14149258 | 0.66 | KIT (0.43) | KITKDM5BJAK2JAK1TYK2 | |
| SCHEMBL24578525 | 0.66 | BRAF (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |